Yarrow Bioscience (NASDAQ:YARW) Issues Quarterly Earnings Results

Yarrow Bioscience (NASDAQ:YARW) announced its earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, FiscalAI reports. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Stock Up 8.8%

Shares of YARW stock opened at $19.63 on Friday. Yarrow Bioscience has a 52-week low of $12.39 and a 52-week high of $46.95. The business has a fifty day simple moving average of $22.09.

Hedge Funds Weigh In On Yarrow Bioscience

Large investors have recently made changes to their positions in the business. Braidwell LP bought a new stake in Yarrow Bioscience during the 2nd quarter valued at approximately $596,000. Susquehanna International Group LLP bought a new position in Yarrow Bioscience in the 2nd quarter worth approximately $77,000. Two Sigma Securities LLC bought a new position in Yarrow Bioscience in the 2nd quarter worth approximately $26,000. Nantahala Capital Management LLC purchased a new stake in Yarrow Bioscience during the 2nd quarter valued at approximately $1,301,400,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Yarrow Bioscience during the 2nd quarter valued at approximately $1,920,000. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

YARW has been the topic of a number of analyst reports. BTIG Research began coverage on Yarrow Bioscience in a research report on Monday, August 3rd. They set a “buy” rating and a $58.00 price objective on the stock. TD Cowen started coverage on shares of Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Finally, Guggenheim began coverage on shares of Yarrow Bioscience in a report on Friday, November 6th. They set a “buy” rating and a $60.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.